You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 1, 2026

Bulk Pharmaceutical API Sources for solifenacin succinate


✉ Email this page to a colleague

« Back to Dashboard


Bulk Pharmaceutical API Sources for solifenacin succinate

Vendor Vendor Homepage Vendor Sku API Url
Molport ⤷  Start Trial MolPort-003-850-268 ⤷  Start Trial
Amadis Chemical ⤷  Start Trial A817166 ⤷  Start Trial
AKos Consulting & Solutions ⤷  Start Trial AKOS015994745 ⤷  Start Trial
MedChemexpress MCE ⤷  Start Trial HY-A0002 ⤷  Start Trial
AbaChemScene ⤷  Start Trial CS-0371 ⤷  Start Trial
>Vendor >Vendor Homepage >Vendor Sku >API Url

Bulk Active Pharmaceutical Ingredient (API) Sources for Solifenacin Succinate

Last updated: February 24, 2026

Where are bulk APIs for solifenacin succinate produced?

Manufacturers produce solifenacin succinate APIs primarily in China, India, and Europe. These regions dominate global supply with varying compliance standards, pricing, and lead times.

Key API producers by region

China

  • Leading API manufacturer globally.
  • Companies such as Zhejiang Medicine Co., Ltd., and Desano International have commercial production lines for solifenacin succinate.
  • Manufacturers often supply to both domestic and international markets.

India

  • Known for low-cost production.
  • Major players include Cipla, Sun Pharmaceutical Industries Ltd., and Aurobindo Pharma.
  • These companies produce APIs that meet international standards, including US FDA and EMA approvals.

Europe

  • Smaller-scale production but high compliance.
  • Companies such as Dr. Reddy’s Laboratories and pharmaceutical contract manufacturing organizations (CMOs) in Germany and Switzerland.

API specifications and regulatory status

Region GMP Compliance Regulatory Approvals Typical Lead Time Price Range (per kg)
China Yes Not always, varies by supplier 4–8 weeks $1,200–$1,800
India Yes, with certifications Usually meets US FDA, EMA requirements 4–6 weeks $1,000–$1,500
Europe Yes Strict standards, GMP-certified 2–4 weeks $2,000–$3,000

Sourcing considerations

  • Regulatory compliance: Ensure supplier holds GMP certification and can provide batch documentation.
  • Quality assurance: Confirm compliance with pharmacopoeias (USP, EP, JP) and cytotoxicity testing.
  • Pricing and lead times: Indian sources are typically less costly with shorter lead times; Chinese sources may offer lower prices but present higher variability in quality documentation.
  • Supply stability: Long-term contracts are recommended to mitigate supply chain disruptions.

Contract Manufacturing Organizations (CMOs)

Major CMOs in the API space include:

  • Famar (Greece)
  • Eurofins Scientific (France)
  • Gurobiotech (India)
  • Bachem (Switzerland)

These organizations can customize API production, provide analytical services, and support regulatory filings.

Supply chain risks

  • Geopolitical tensions affect Chinese API exports.
  • Shipping delays due to COVID-19 impact Indian and Chinese suppliers.
  • Regulatory updates in importing countries can restrict certain sources.

Summary of sourcing options

Source Type Advantages Disadvantages
Chinese suppliers Competitive pricing, large capacity Quality verification, IP concerns
Indian suppliers Cost-effective, meet international standards Varied compliance levels, longer certification process
European CMOs High regulatory compliance, reliable supply Higher cost, limited capacity

Conclusion

Bulk API sourcing for solifenacin succinate centers on Chinese and Indian manufacturers. Selecting suppliers depends on cost constraints, regulatory requirements, and supply chain stability. Contracts with reputable CMOs and thorough due diligence reduce risk.


Key Takeaways

  • China and India dominate the solifenacin succinate API supply chain.
  • Indian sources typically match regulatory standards at lower costs compared to Chinese providers.
  • European suppliers focus on high compliance but come with higher pricing.
  • Supply chain stability requires vetting supplier certifications and capacity.
  • Contract manufacturing organizations support customization and quality assurance.

FAQs

  1. What are the main risks in sourcing solifenacin succinate API? Supply chain disruptions, regulatory non-compliance, and quality variability pose primary risks.

  2. Can I source APIs from regional suppliers outside China and India? Yes, but supply volume and compliance standards may be limited. Europe and North America have fewer options but higher standards.

  3. What certifications should suppliers possess? GMP certification aligned with ICH guidelines, and compliance with USP, EP, or JP standards.

  4. How does pricing vary by region? Prices tend to be lowest in India (\$1,000–\$1,500 per kg), slightly higher in China (\$1,200–\$1,800 per kg), and highest in Europe (\$2,000–\$3,000 per kg).

  5. How long does it take to scale production? Lead times typically range from 2 to 8 weeks, depending on supplier location, certification, and batch size.


References

[1] U.S. Food and Drug Administration. (2022). Guidance for Industry: Good Manufacturing Practices.
[2] European Medicines Agency. (2021). Manufacturing and quality control standards.
[3] Global Trade Analysis Project. (2022). API manufacturing cost analysis.
[4] Pharmaceutical Technology. (2022). Trends in API sourcing and supply chain risks.
[5] Indian Pharmacopeia Commission. (2020). API regulatory standards.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.